Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Nov
03
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
Current Public Knowledge Rates on Alcohol and Cancer Risks
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo